Haris Ali, MD, discusses research supporting the use of ruxolitinib for the treatment of myelofibrosis.
Haris Ali, MD, a hematologist/oncologist and associate clinical professor, Department of Hematology & Hematopoietic Cell Transplantation at the City of Hope Comprehensive Cancer Center, discusses research supporting the use of ruxolitinib (Jakafi) for the treatment of myelofibrosis.
According to Ali, COMFORT-1 (NCT00952289) and COMFORT-2 (NCT00934544), showed that ruxolitinib showed good responses when compared to best available treatment or other supportive treatments. It was also shown beneficial for the treatment of polycythemia vera.
Ruxolitinib was recently approved for the treatment of graft versus host disease (GvHD) and has shown promise in chronic GvHD. According to Ali, this is due to the unique mechanism of improving inflammation, which is the main driver in patients with myelofibrosis, other myeloproliferative neoplasms, and GvHD.
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors
June 17th 2024During a Case-Based Roundtable® event, Kristen Pettit, MD, moderated a discussion on which disease features of myelofibrosis are most challenging and when to use JAK inhibitors in the first article of a 2-part series.
Read More
MOST Study Shows High Rates of Disease Progression in Low/Intermediate-Risk MF Over 4 Years
June 14th 2024MOST study shows high rates of disease progression in low/intermediate-risk myelofibrosis over 4 years, with the rate increasing over time. This offers valuable insight for a patient group with limited prior data.
Read More
Podoltsev Reviews JAK Inhibition Options for Patient With Primary Myelofibrosis
June 5th 2024During a Case-Based Roundtable® event, Nikolai Podoltsev, MD, PhD, discussed appropriate JAK inhibitor therapy options for a 62-year-old patient with myelofibrosis who had potentially declining hemoglobin and platelet counts.
Read More
Ruxolitinib Offers Durable Hematocrit Control, Low Thrombosis Risk in PV
May 30th 2024In an interview with Targeted Oncology, Aleksander L. Chojecki, MD, discussed findings from his research on hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib.
Read More